Curated News
By: NewsRamp Editorial Staff
December 04, 2025
Volition's Biomarker Chosen for French Sepsis Detection Program
TLDR
- VolitionRx's Nu.Q NETs H3.1 assay was selected for a €6.3 million French government program, giving the company a competitive edge in early sepsis detection technology.
- Volition's biomarker assay works by detecting H3.1 levels in blood, delivering results within one hour on automated analyzers to identify sepsis severity and predict outcomes.
- This technology could save lives by enabling earlier sepsis detection, improving patient outcomes and reducing healthcare burdens through better emergency care decisions.
- A single blood test now outperforms established severity scores in predicting sepsis outcomes, potentially transforming emergency medicine with rapid, automated biomarker analysis.
Impact - Why it Matters
This news matters because sepsis is a life-threatening condition that affects millions globally, with early detection being crucial for survival and reducing long-term health complications. The selection of Volition's Nu.Q® H3.1 assay for the DETECSEPS program could lead to faster, more accurate diagnosis in emergency settings, potentially saving lives and lowering healthcare costs. For patients, it means quicker access to treatment, improved recovery prospects, and better quality of life. For the healthcare industry, it represents an advancement in precision medicine, leveraging epigenetics to enhance diagnostic tools. This development highlights the growing role of innovative biomarkers in transforming patient care and addressing public health challenges like sepsis, which often has high mortality rates due to delayed intervention.
Summary
VolitionRx Ltd. (NYSE American: VNRX), a multi-national epigenetics company, has achieved a significant milestone with its Nu.Q® NETs H3.1 assay being selected as the sole biomarker for the French government-funded "DETECSEPS" program. This initiative, part of the France 2030 plan and led by the IHU SEPSIS with a €6.3 million grant, aims to revolutionize early sepsis detection in emergency care. Professor Djillali Annane, Scientific Director of DETECSEPS, emphasized that combining Volition's biomarker with the clinical NEWS2 score could dramatically improve early identification, noting its strong correlation with disease severity and superior prognostic utility for outcomes like organ failure and mortality compared to established scores such as APACHE II and SOFA.
In the announcement, Volition's Chief Medical Officer, Dr. Andrew Retter, highlighted the practical benefits of the Nu.Q® H3.1 assay, which can deliver results within one hour on the Immunodiagnostic Systems (IDS) i10® automated analyzer. This rapid turnaround is poised to enhance emergency decision-making, potentially saving lives, improving survivors' quality of life, and reducing the burden on healthcare systems. Volition is providing the assay pro-bono for this evaluation, underscoring its commitment to advancing epigenetics for disease detection. The company, with research hubs in Belgium, the U.S., and London, focuses on developing cost-effective blood tests for diseases like sepsis and some cancers, aiming to prolong and improve patients' lives through earlier detection.
The news was disseminated through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio of IBN, which offers extensive wire solutions, editorial syndication, and social media distribution to amplify such breakthroughs. For more details, readers can visit the full press release via the provided link. This development marks a pivotal step in leveraging epigenetic science to address critical healthcare challenges, with potential global implications for emergency medicine and patient outcomes.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Volition's Biomarker Chosen for French Sepsis Detection Program
